New York Clinical Trials Report — May 2026

For New Yorkers considering participation in clinical research, May 2026 presents a crucial period, particularly for those interested in studies with rapidly approaching enrollment deadlines. Across the state, 365 clinical trials are scheduled to close within the next 90 days. This includes 74 studies that are actively seeking healthy volunteers, offering a significant opportunity for individuals without specific health conditions to contribute to medical advancements before these options are no longer available.

Time is Running Out: Trials Nearing Enrollment Close

Patients managing certain health conditions should also be aware of impending deadlines to join research. A range of trials focused on various cancers, neurological conditions, and mental health challenges are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer (11 trials)
• Cancer (7 trials)
• Prostate cancer (6 trials)
• Pancreatic ductal adenocarcinoma (6 trials)
• Ovarian cancer (5 trials)
• Solid tumor (4 trials)
• Pancreatic cancer (4 trials)
• Depression (4 trials)
• Lung cancer (4 trials)
• Mild cognitive impairment (4 trials)

If you or a loved one are affected by these conditions, exploring these opportunities promptly is advisable to avoid missing out on potential new treatments or diagnostic approaches.

New Horizons: Major Research Initiatives Launch in New York

This month, New York saw the opening of 29 new clinical trials, adding to the state's robust research landscape. While this number is lower compared to the 78 trials that launched in March 2026, these new studies include several high-profile Phase 2 and 3 initiatives from major sponsors, offering participants access to cutting-edge research.

Among the most notable new trials are several large-scale studies from Novo Nordisk A/S, focusing on metabolic and cardiovascular health, alongside innovative research from other leading institutions and companies:

• Novo Nordisk A/S is sponsoring NCT07567001, a Phase 3 study titled "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This substantial trial aims to enroll 5,610 participants globally, evaluating the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight.
• Another significant Phase 3 study from Novo Nordisk A/S is NCT07564414, "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight." This trial seeks to enroll 2,500 participants to assess the safety and effectiveness of CagriSema for body weight loss in people with obesity, with or without type 2 diabetes.
• Natural Cycles is leading NCT07566793, an observational study titled "Validation of Effectiveness on NaturalCycles Users." This study aims to measure the effectiveness of the Natural Cycles digital birth control application in preventing pregnancy, enrolling 2,000 sexually active women aged 18 to 35.
• Tarsus Pharmaceuticals, Inc. is sponsoring NCT07562087, a Phase 2 study titled "A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure." This trial is designed to evaluate the safety, tolerability, and pharmacokinetics of an orally administered treatment for healthy adult participants, with a target enrollment of 700.
• The Ohio State University is leading NCT07567040, a Phase 4 study named "Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical Trial." This trial will involve 664 participants and test whether the onset of nearsightedness (myopia) is delayed in children randomized to nightly drops of 0.05% atropine compared to a placebo. This study includes children as participants.
• Immuneering Corporation is sponsoring NCT07562152, a Phase 3 study titled "Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma." This study aims to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with standard of care GnP alone, with 510 participants.
• Two additional Phase 3 studies from Novo Nordisk A/S, NCT07571005 (AMAZE 3) and NCT07571109 (AMAZE 4), are investigating the medicine NNC0487-0111 for people with excess body weight and obstructive sleep apnoea. Each study aims to enroll 300 participants, with AMAZE 3 focusing on those not treated with positive airway pressure and AMAZE 4 on those who are.

New Research Across New York's Cities and Conditions

New York continues to be a hub for diverse clinical research, with 4,418 clinical trials currently recruiting across 202 cities and 2,999 research sites statewide. This month's 29 new trials are exploring a variety of conditions, from prevalent health issues to more specialized areas. The conditions targeted by these new studies include:

• Obesity (4 trials)
• Lymphoma (2 trials)
• Obstructive sleep apnoea (2 trials)
• Overweight (2 trials)
• Back pain (1 trial)
• Cardiotoxicity (1 trial)
• Allograft (1 trial)
• Chemotherapy (1 trial)
• Anthracycline-induced cardiotoxicity (1 trial)
• Clonidine (1 trial)

Geographically, the majority of new research initiatives this month are concentrated in New York City, with 20 of the 29 new trials opening there. However, opportunities are also available in other parts of the state, including Rochester (3 new trials), Buffalo (2 new trials), Brooklyn (2 new trials), and Albany (2 new trials). Other cities like Harrison, Manhattan, Middletown, Mineola, and Rockville Centre each saw the launch of one new trial, indicating a broad distribution of research opportunities across the state.

Participation Opportunities: Healthy Volunteers and Specific Demographics

Clinical trial participation is open to a wide range of individuals, reflecting the diverse needs of medical research. Of the 29 new trials launched this month, 21 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 7 new trials are open to children, offering opportunities for younger participants to engage in research that could benefit their age group. There are also specific opportunities, with 3 new trials designed for female-only participants and 1 for male-only participants.

For individuals without a specific medical condition, there are significant opportunities to contribute. 8 of the 29 new trials this month are actively seeking healthy volunteers. Across New York, a total of 573 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research and contributing to the development of new treatments and preventions.

Academic institutions continue to play a vital role in New York's research ecosystem, with NYU Langone Health sponsoring 4 of the new trials and Columbia University sponsoring 2. Industry sponsors, including Novo Nordisk A/S, are also driving significant research efforts, accounting for 4 of the new studies this month. Overall, 12 of the new trials are industry-sponsored, while 17 are led by academic or other non-industry organizations.

As we move further into 2026, New York's dynamic research environment will continue to evolve, bringing forth new opportunities for residents to engage with cutting-edge medical science and contribute to a healthier future.